ArticlePloS one2020
Vancomycin and nisin A are effective against biofilms of multi-drug resistant Staphylococcus aureus isolates from human milk.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Bacteriocins in Veterinary Medicine: From Antibiotic Limitations to Targeted Solutions.International journal of molecular sciences · 2026Review
- The Effects of Low Concentrations of Nisin on Biofilm Formation byPathogens (Basel, Switzerland) · 2025Article
- In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection.Antibiotics (Basel, Switzerland) · 2025Article
- Bactofencin A Displays a Delayed Killing Effect on a Clinical Strain ofAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial resistance, virulence profiling, and drug repurposing analysis of Staphylococcus aureus from camel mastitis.Veterinary research communications · 2024Article
- Combination antimicrobial therapy: in vitro synergistic effect of anti-staphylococcal drug oxacillin with antimicrobial peptide nisin against Staphylococcus epidermidis clinical isolates and Staphylococcus aureus biofilms.Annals of clinical microbiology and antimicrobials · 2024Article
- Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates.Frontiers in microbiology · 2024Article
- Specific Binding of the α-Component of the Lantibiotic Lichenicidin to the Peptidoglycan Precursor Lipid II Predetermines Its Antimicrobial Activity.International journal of molecular sciences · 2023Article
- Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance.Microorganisms · 2022Review
- Isolation, Characterization, and Effect on Biofilm Formation of Bacteriocin Produced byBioMed research international · 2022Article
- Influence of Fluoride-ResistantFrontiers in cellular and infection microbiology · 2022Article
- Efficiency of Antimicrobial Peptides Against Multidrug-Resistant Staphylococcal Pathogens.Frontiers in microbiology · 2022Review
- Lacticaseicin 30 and Colistin as a Promising Antibiotic Formulation against Gram-Negative β-Lactamase-Producing Strains and Colistin-Resistant Strains.Antibiotics (Basel, Switzerland) · 2021Article
- Influence of Nisin-Biogel at Subinhibitory Concentrations on Virulence Expression inAntibiotics (Basel, Switzerland) · 2021Article
- Susceptibility to Nisin, Bactofencin, Pediocin and Reuterin of Multidrug ResistantAntibiotics (Basel, Switzerland) · 2021Article
- A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.Applied and environmental microbiology · 2021Article
- Prevalence and Characteristics ofFrontiers in microbiology · 2021Article
- Biofilm-Forming Ability and Effect of Sanitation Agents on Biofilm-Control of ThermophilePolish journal of microbiology · 2020Article
- Human milk microbiota in sub-acute lactational mastitis induces inflammation and undergoes changes in composition, diversity and load.Scientific reports · 2020Article
- Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.International journal of environmental research and public health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human milk provides complete nutrition for infants and at the same time promotes the growth of specific bacteria in the infant gastrointestinal tract. Breastfeeding can often be discontinued due to mastitis which is an inflammation of the breast tissue. We isolated 18 Staphylococcus aureus strains from milk donated by healthy (n = 6), subclinical (n = 6), and mastitic (n = 6) mothers, two strains of which were VISA (Vancomycin Intermediate S. aureus). All tested strains (n = 12) were able to form biofilms. We then examined the impact of nisin A and vancomycin alone and in combination on biofilm formation and eradication of selected strains (n = 8). We observed strain-specific responses, with the combinatorial treatment at 1/4X MIC (for both singularly) significantly inhibiting biofilm formation for seven out of eight strains when compared with nisin A or vancomycin alone. None of the selected treatments were able to eradicate pre-formed biofilms. Finally, we selected two strains, namely a VISA (APC3814H) and a strong biofilm former (APC3912CM) and used confocal microscopy to evaluate the effects of the antimicrobial agents at 1X MIC on biofilm inhibition and eradication. All treatments inhibited biofilm formation of APC3814H but were ineffective in eradicating a pre-formed biofilm. Single treatments at 1X MIC against APC3912CM cells did not prevent biofilm formation whereas combination treatment caused increased death of APC3912CM cells. Finally, the combination treatment reduced the thickness of the pre-formed APC3912CM biofilm as compared with the single treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.